No 1
TSH-RECEPTOR STRUCTURE AND MECHANISM OF ACTIVATION
Ralf Paschke
Medizinische Klinik, Universität Leipzig, Leipzig
printed version
Holger Jaeschke1, Maren Claus1, Gunnar Kleinau2, Gerd Krause2 , Ralf Paschke1
1
III. Medical Department, University of Leipzig, Ph.-Rosenthal-Str. 27, D-04103 Leipzig,
Germany
2
Forschungsinstitut für molekulare Pharmakologie, Robert-Rössle-Str. 10, D-13125 Berlin,
Germany
Correspondence:
Ralf Paschke, M.D.
III. Medical Department, University of Leipzig
Ph.-Rosenthal-Str. 27
04103 Leipzig
Phone: 49-341-9713200
Fax: 49-341-9713209
Email: pasr@medizin.uni-leipzig.de
In a previous review (1) on the structure and mechanism of activation of the thyroid
stimulating hormone receptor (TSHR), published in 2001, we summarized the evidence in
relation to structure and function of the TSHR. Since 2001 several new and important insights
in TSHR structure and signal generation have been reported. In this review we will summarize
these recent key findings concerning the TSHR research of the last years.
The thyroid stimulating hormone (TSH) as a member of the glycoprotein hormone family is
secreted by the pituitary gland and controls thyroid function and proliferation via interaction
with the membrane associated TSHR. Binding of TSH results in activation of the G proteincoupled TSHR and in stimulation of second messenger pathways, like cyclic adenosine
monophosphate (cAMP), inositolphosphates (IPs) and diacylglycerol (DAG). Intracellular
accumulation of these second messengers leads to modification of different physiological
properties of thyroid cells.
The TSHR belongs together with the choriogonadotropin/luteinizing hormone receptor
(CG/LHR), follicle stimulating hormone receptor (FSHR) and leucin rich repeat containing
glycoprotein receptors (LGRs) to the subfamily of glycoprotein hormone receptors (GPHR) (24). The TSHR, LHR and FSHR are characterized by a large N-terminal extracellular domain
(ECD), a seven transmembrane spanning helix motif (TM1-7) connected by three extra- and
three intracellular loops (ECL1-3; ICL1-3) and a C-terminal intracellular domain.
Despite functional characterization of numerous in vivo TSHR mutants less is known about
the precise mechanisms of recpetor activation. The understanding is hindered by the lack of
information about the three-dimensional structure of the TSHR. One reason is the small
number of functionally characterized amino acid exchanges for the large extracellular domain
and the extracellular loops of the TSHR. The major part of naturally occurring mutations is
located in the TMs (5, www.uni-leipzig.de/~innere/tsh/). The occurrence of in vivo activating
mutations revealed first insights into intra- and intermolecular structure-function relationships
of the TSHR and led to new approaches for the elucidation of the mechanism of TSHR
activation by site-directed mutagenesis and molecular modelling.
Extracellular Domain and Extracellular Loops
The large N-terminal extracellular domain consists of five molecular sections: (i) an N-terminal
Cysteine-box-1 (C-b1) (hTSHR: 1-54), (ii) a 230 aa spanning leucin rich repeat motif (LRR)
(hTSHR: 55-279), (iii) the central Cysteine-box-2 (C-b2) (hTSHR: 280-314), (iv) a TSHR
specific 50 aa insertion (hTSHR: 317-366) and (v) the C-terminal Cysteine-box-3 (C-b3)
(hTSHR: 370-410). (6, Figure).
LEGEND: TSHR: cartoon representing a molecular model (6) for the very tight packing of the
ectodomain (LRR, Cysteine-box-2,Cysteine-box-3) being located very close to or even in
between the extracellular loops of the serpentine domain. A new LRR template based on the
Nogo receptor with much higher sequence similarity to the TSHR was introduced, whose
‘scythe blade’ shape also allows an interaction of the hormone parallel to the LRR structure.
Furthermore, a new template for Cysteine-boxes -2 and –3 was identified based on a complex
structure of the chemokine IL8 and a portion of the N-terminal tail of the IL8 receptor. These
findings also support the hypothesis of a disulfide bridge between Cys398/Cys408 (C-b3)
either to Cys283/Cys284 (C-b2) or in a reverse manner with Cys408/Cys398. (6, 20).
Furthermore, the hydrophilic amino acids Asp403, Glu404 and Asn406 of C-b3, spatially
located in proximity to Ser281, are likely to be involved in intramolecular signal transduction
from the ECD towards the serpentine domain.
The largest structural characteristic of the extracellular domain is the leucine rich repeat (LRR)
motif (2-4). The LRRs are not only a direct interaction partner for the ligand, but also have an
essential role for receptor function. Mutagenesis of the N-terminal part of the TSHR and
CG/LHR has shown that activity of the TSHR can be directly influenced by changes in the
extracellular domain (7, 8). Based on the crystal structure of LRR containing proteins only the
structural properties of the LRRs in the middle of the ECD sequence of the GPHRs were
determined (9, 10) To evaluate an optimal structure template for the LRR Kleinau et al. (6)
determined the LRR motif based on the Nogo receptor (11) as the best matching motif for the
LRR for all three human GPHRs. To investigate the influence of the ECD for TSHR activation
in more detail, Zhang et al. (12) deleted the ECD. This resulted in a strong constitutive
activation of the receptor. A similar experiment described the loss of constitutive activity of the
naturally occurring mutations Ile486Phe (ECL1) and Ile568Thr (ECL2) after deletion of the
ECD, which implies that the ECD likely interacts with regions of the ECLs as a linked inverse
agonist to maintain the inactive receptor conformation (13). In addition, these findings suggest
that the structure of the ECD alternates from a tethered inverse agonist to an agonist in the
process of receptor activation. Another experimental approach for the CG/LHR suggests that
a structure within the ECD serves as an agonist for the ECLs as part of the transmembrane
domain after agonist binding or mutational alterations (14). These findings underline the
importance of the ECD and the ECLs in the process of TSHR activation and support a model
in which the ectodomain acts as a silencer of the serpentine domain of the receptor. The
current research is mainly focused on the identification of residues or epitopes in the ECD and
ECLs, respectively, which are involved in the maintenance of the inactive conformation of the
TSHR. Ser281 is the only position in the ECD, which is affected by constitutively activating in
vivo mutations (15-18), and it was intensively characterized together with the surrounding
residues (C-b2). The highly conserved Ser281 is situated in the hinge region between the
LRR motif of the ECD and the TMs like the homologous positions Ser277 in the CG/LHR and
S273 in the FSHR. Mutagenesis of amino acids Pro280, Cys283 and Cys284 in the vicinity of
Ser281 also led to constitutive activation of the TSHR (19). In addition, recent studies on the
corresponding position Ser277 in the CG/LHR (TSHR: Ser281) by substitution of all other 19
amino acids suggest that Ser277 is an integral part of a loop like epitope that may be involved
in stability and signal generation of the CG/LHR (14, 20). In fact, 15 substitutions at position
Ser277 in the CG/LHR led to constitutive activation of the receptor. Taken together, the C-b2
epitope 279YPSHCC284 can probably act as an intramolecular switch for receptor activation.
In another approach a systematic search with fragments of the ECD in the protein structure
database (PDB) was performed (6). Based on sequence similarities two new structural
templates were identified. First, a new LRR template based on the Nogo receptor with much
higher sequence similarity to the TSHR was introduced, whose ‘scythe blade’ shape allows
also an interaction of the hormone parallel to the LRR structure. Second, a new template for
C-b2 and C-b3 was identified. This template showed homologous properties to the structure
of the chemokine IL8 and to a portion of the N-terminal tail of the IL8 receptor. In this way
sequence similarities of C-b2 to the chemokine IL8 and C-b3 to the IL8 receptor, respectively,
were determined. The very tight packing of LRR, C-b2 and C-b3 with the extracellular loops
also supports the hypothesis of disulfide bridges between Cys398/Cys408 (C-b3) or between
one or both of these cysteins with Cys283/Cys284 (C-b2) and/or Cys408/Cys398. (6, 21).
Furthermore, the hydrophilic amino acids Asp403, Glu404 and Asn406 of C-b3 were likely to
be involved in intramolecular signal transduction from the ECD towards the serpentine domain
(6). Substitution of these residues by amino acids with an opposite charge and the smallest
nonpolar amino acid alanine, respectively, leads to constitutive activation of the TSHR in three
of five mutants (Asp403Ala, Glu404Lys, Asn406Ala). Residues Asp403 and Asn406 are highly
conserved in GPHRs and alanine substitutions at these positions lead to constitutive
activation of the receptor. Interestingly, Glu404, a specific amino acid for the TSHR, showed
no differences in basal cAMP accumulation when mutated to alanine, whereas Glu404Lys
revealed a strong basal cAMP accumulation. The authors suggest a spatial proximity of the
epitope Asp403-Asn406 (C-b3) to the Ser281 epitope (C-b2) based on combined data from
homology models and functional data. It is important in this context that these two epitopes in
the ECD are the only ones that have been reported to lead to constitutive activation of the
TSHR by in vivo mutations (Ser281Thr/Ile/Asn) or mutagenesis (Asp403-Asn406). Based on
sequence similarities between the three members of the GPHRs it has been suggested that
mutations of the CG/LHR and FSHR at positions corresponding to Asp403-Asn406 in the
TSHR also cause constitutive activity (Figure).
To provide a hypothesis for interactions between the ECD and ECLs (12, 13) more knowledge
about the structural and functional properties of these regions is necessary. In contrast to the
CG/LHR and FSHR, only very few functionally characterized in vivo and in vitro mutations in
the extracellular loops of the TSHR are available. Most of them are in vivo mutations:
Thr477Ile (ECL1), Ile486Phe, Met (ECL1), Ile568Thr (ECL2), Asn650Thr (ECL3), Val656Phe
(ECL3) and del658-661 (ECL3) (5). Only position Asp474 in the TSHR has been intensively
characterized by mutagenesis (22). The ECLs seem to be important for both, the interactions
with the ECD and for signal transduction towards the serpentine domain. Agretti et al. (23)
generated a receptor harboring the inactivating mutation Thr477Ile in the ECL1 and the
activating mutation Pro639Ser in the 6th transmembrane segment (5, 24), resulting in a
dominant effect of the activating Pro639Ser mutation. Interestingly, Thr477Ile was
characterized by an impaired cell surface expression and Pro639Ser showed a cell surface
expression comparable to the wt TSHR. However, the double mutant Thr477Ile/Pro639Ser
was expressed on the cell surface like the single mutant Pro639Ser. This suggested that not
only signal pathways but also structural properties between the ECL1 and TM6 were affected,
which are necessary for correct folding and trafficking to the cell surface. In a second
approach these authors combined two constitutively activating mutations (Ile486Phe in the
ECL1 and Pro639Ser in the ECL2), which led to an increased basal cAMP accumulation. This
observation was also reported by Kosugi et al. (25) and Angelova et al. (26) for the CG/LHR.
Much more is known about the ECLs of the CG/LHR and FSHR, especially for the ECL3. An
alanine scan of the ECL3 including residues Lys580-Lys590 of the FSHR (TSHR: An650Lys660) identified several residues which are crucial for activation of the Gs and Gq signal
pathway and for hormone binding (27, 28). Based on the highly conserved amino acid
sequence of the ECL3 within the GPHRs it is likely that the ECL3 also plays an important role
in signal generation and hormone binding for the CG/LHR and TSHR. Only for position
Lys660 (unpublished data) in the TSHR and Lys583 in the CG/LHR (corresponding to Lys590
in the FSHR) functional data are available (29). Comparing the results regarding cell surface
expression, cAMP and IP synthesis and hormone binding similar effects of this position could
be determined within these GPHRs. In addition to the ECL3 of the FSHR, Ryu et al. (30)
characterized the ECL2 of the CG/LHR by an alanine scan. Also for the ECL2 several
residues, which are involved in signal generation and hormone binding, were identified. Taken
together, these data can be used for refining the three dimensional models of the receptors to
determine residues which are interaction points between the ECD and the transmembrane
domain.
Transmembrane Domain
The transmembrane domains of GPHR consist of seven helices connected by three
extracellular and three intracellular loops. Based on sequence alignments of the G proteincoupled receptors a homology of more than 70% could be determined (2-4). New insights into
structural relationships of the TMs were possible with the description of the x-ray crystal
structure of the bovine rhodopsin with a high resolution (31). Due to the high homology of
GPCRs within their TMs this structure model is used as a template for many members of the
large superfamily of G protein-coupled receptors. In addition, this model allowed many groups
to provide new important insights into the architecture and side chain orientations of the TMs.
The TMs of the TSHR are characterized by a large number of constitutively activating in vivo
mutations. Most of them are located in TM6 between residues 629 and 639 (5). Furthermore,
naturally occurring mutations were identified in TM2, TM3, TM5 and TM7. The high number of
in vivo mutations underlines the importance of the TMs with regard to stabilization of the
inactive receptor conformation. In particular, interactions between TM5-TM6 and TM6-TM7
seem to be involved in maintaining the native receptor conformation. Neumann et al. (32)
have identified a hydrogen bond between Asp633 (TM6) and Asn674 (TM7) by a combined
approach of mutagenesis and modeling guided by naturally occurring mutations. This finding
was supported by Kosugi et al. (33) and Lin et al. (34) which have characterized the
homologous position Asp578 in LHR (corresponding to Asp633 in TSHR) by mutagenesis. A
breakdown of this interaction between TM6 and TM7 leads to a change in receptor
conformation and finally to a constitutive activation of the receptor. A recent report
demonstrated that residue Met389 in the LHR (corresponding to Met453 in TSHR) is essential
to maintain the inactive receptor conformation by interactions with the highly conserved
residues Ile460 in TM3 (Ile515 in TSHR), Met571 in TM6 (Met626 in TSHR) and Tyr623 in
TM7 (Tyr678 in TSHR) (35). Due to the fact that mutation of the homologous residue Met453
in the TSHR also causes constitutive activity, it is likely that a similar network of interactions
exists in the TSHR (36-39).
Intracellular Loops
A common feature of all GPCRs is their interaction with G-proteins and subsequently the
activation of downstream signaling cascades. Although many studies have focused on the
molecular mechanisms of G-protein activation, conserved structure motives participating in
the processes of G-protein recognition and selectivity have not been identified yet (40, 41).
However, studies on several GPCRs revealed that residues, which are involved in G-protein
coupling and selectivity, are primarily localized at the transmembrane/cytoplasmic borders
between TM3/ICL2, TM5/ICL3 and ICL3/TM6 (42). Similarly, ICLs 2 and 3 of the TSHR were
found to be important for recognition and selective activation of G αs and Gαq (1, 43). Initially,
studies on chimeric TSHRs containing homologous sequences of the α1- and β2 adrenergic
receptors revealed the impact of the ICL2 for cAMP- and IP signaling (44). Kosugi et al.
demonstrated the importance of the middle part of the ICL2 for G s activation and identified
amino acids 528-532 as important for Gq mediated IP production. Mutagenesis studies of the
LH and FSH receptor also provided evidence for an important functional role of several amino
acid residues within ICL2 (45, 46). However, only single selected residues in ICL2 were
substituted in these studies. To further investigate the influence of this domain on TSHR
signaling, deletion studies and alanine-scanning mutagenesis were carried out (43). Deletions
of four to five residues and their corresponding multiple alanine substitutions were introduced
into ICL2. Residues I523-D530, comprising mainly the N-terminal half of ICL2, appeared to be
critical for Gs- and Gq-mediated signaling. A single alanine substitution screening within ICL2
revealed hydrophobic residue M527 in particular and to lesser extents F525, R528, L529 and
D530 as residues that selectively abolished or strongly impaired G q-activation. Further, double
mutants between residues in ICL2 and 3 suggested interactions between these loops in the
vicinity of Phe525 and Thr607, indicating a conformational cooperation between ICLs 2 and 3
during Gq-activation by TSHR.
So far, constitutively activating mutations have only been identified in the ICL3 of the TSHR,
but not in the ICL1 and 2 or the C-terminus (47). Both constitutively activating point mutations
in ICL 3 Asp619Gly and Ala623Ile are localized in the C-terminal part of the loop and at the
ICL3/TM6 junction. Further, the activating deletion mutation del613-621 also includes the Cterminus of ICL3. Mutagenesis studies on hybrid angiotensin II AT1 and AT2 receptors
showed, that the N-terminal part of ICL3 is primarily responsible for Gq recognition. Further, for
the AT1 receptor it was shown that residues in the C-terminus of ICL3 also contribute to Gq
activation. Investigation of chimeric TSHR containing homologous sequences of the α1- and
β2-adrenergic receptors revealed the importance of N- and C-terminal amino acids in ICL3 for
Gq mediated signaling (48). In this work Kosugi et al. showed that substitution of residues in
the N- and C-termini of ICL3 abolished Gq mediated IP formation, whereas mutation of amino
acids in the middle portion had no effect on TSHR signaling. In contrast, substitution of amino
acids 617-620 resulted in increased basal activity regarding to the Gs – cAMP pathway. Based
on the constitutively active in vivo deletion del613-621, different deletion- and alanine
substitution mutants were characterized (49). Thereby, it has been shown that not the loss of
a specific group of mino acids residues is decisive for the constitutive activation of the TSHR.
However, shortening of ICL3 leads to a relative movement of TM6 towards the cytoplasm
enabling critical transmembrane portions to interact with Gαs. This assumption is supported by
recent work of Janz et al. (50) demonstrating interactions of transducin with hydrophobic
residues in TM6 following the activation of Rhodopsin. Moreover, the conserved Asp619 at
the ICL3/TM6 junction was found to be necessary for maintaining the inactive conformation of
TSHR and of CG/LHR as well (49). It has been suggested that Asp619 is involved in a helixcapping structure, indicating that the inactive receptor state is stabilized by interactions
between residues within the helix of ICL3/TM6 junction and adjacent structures.
In addition to constitutively activating and inactivating in vivo mutations, several
polymorphisms were identified in the TSH receptor gene. The most frequently found
polymorphisms are Ile606Met (ICL3) and Ala703Gly, Gln703Glu and Asp727Glu in the Cterminal tail. Several studies produced controversial results regarding the association between
these polymorphisms and thyroid diseases. Gabriel et al. (51) found Asp727Glu to be an
important factor in the pathogenesis of toxic multinodular goiter, whereas Ile606Met,
Ala703Gly and Gln703Glu had no effect. In addition, Asp727Glu was also postulated to be
involved in the development of Graves' Disease (52). In contrast, other studies found no
correlation between Asp727Glu or other polymorphisms and the appearance of thyroid
disorders (53, 54, 55). In the context of the wild type TSHR, the polymorphism Asp727Glu
does not seem to be functionally important. Interestingly, both basal and TSH stimulated
cAMP levels of the constitutively activating mutant Ala593Asn could be significantly reduced
by generation of the Ala593Asn/Asp727Glu double mutant (56). This finding suggests
possible unknown properties of TSH receptor polymorphisms which should be further
investigated.
Conclusions
The identification of activating and inactivating mutations has revealed first insights into TSHR
activation and intramolecular interactions. The combination of site-directed mutagenesis and
molecular modelling represents a valuable tool for understanding of structure-function
relationships and will lead to a continuous refining of the 3D structure of the TSHR. This
improved THSR model will have the potential for rational design of new therapeutical
compounds, the development of TSHR agonists, antagonists or superagonists and can help
to understand the molecular pathogenesis of thyroid diseases.
REFERENCES
1. Wonerow P, Neumann S, Gudermann T et al. Thyrotropin receptor mutations as a tool
to understand thyrotropin receptor action. J Mol Med. Dec;79(12):707-21, 2001
2. Szkudlinski MW, Fremont V, Ronin C et al. Thyroid-stimulating hormone and thyroidstimulating hormone receptor structure-function relationships. Physiol Rev. Apr;82(2):473502, 2002
3. Ascoli M, Fanelli F, Segaloff DL. The Lutropin/Chriogonadotropin Receptor, A
Perspective. 2002 Endocr Rev Apr;23(2):141-74, 2002
4. Simoni M, Gromoll J, Nieschlag E. The Follicle-Stimulating Hormone Receptor:
Biochemistry, Molecular Biology, Physiology, and Pathophysiology. Endocr Rev.
Dec;18(6):739-73, 1997
5. Fuhrer D, Lachmund P, Nebel IT et al. The thyrotropin receptor mutation database:
update 2003. Thyroid. Dec;13(12):1123-6, 2003
6. Kleinau G, Jaeschke H, Neumann S et al. Identification of a novel epitope in the TSH
receptor ectodomain acting as intramolecular signalling interface. J Biol Chem. Dec
3;279(49):51590-600. 2004
7. Smits G, Campillo M, Govaerts C et al. Glycoprotein hormone receptors: determinants
in leucine-rich repeats responsible for ligand specificity. EMBO J. Jun 2;22(11):26922703, 2003
8. Costagliola S, Panneels V, Bonomi M et al. Tyrosine sulfation is required for agonist
recognition by glycoprotein hormone receptors. EMBO J. Feb 15;21(4):504-13, 2002
9. Enkhbayar P, Kamiya M, Osaki M et al. Structural principles of leucine-rich repeat
(LRR) proteins. Proteins. Feb 15;54(3):394-403, 2004
10. Kobe B, Deisenhofer J. Crystal structure of porcine ribonuclease inhibitor, a protein with
leucine-rich repeats. Nature. Dec 23-30;366(6457):751-6, 1993
11. He XL, Bazan JF, McDermott G et al. Structure of the Nogo receptor ectodomain: a
recognition module implicated in myelin inhibition. Neuron. Apr 24;38(2):177-85. 2003
12. Zhang M, Tong KP, Fremont V et al. The extracellular domain suppresses constitutive
activity of the transmembrane domain of the human TSH receptor: implications for
hormone-receptor interaction and antagonist design. Endocrinology. Sep;141(9):3514-7,
2000
13. Vlaeminck-Guillem V, Ho SC, Rodien P et al. Activation of the cAMP pathway by the
TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an
agonist. Mol Endocrinol. Apr;16(4):736-46, 2002
14. Sangkuhl K, Schulz A, Schultz G et al. Structural requirements for mutational
lutropin/choriogonadotropin receptor activation. J Biol Chem. Dec 6;277(49):47748-55
2002
15. Duprez L, Parma J, Costagliola S et al. Constitutive activation of the TSH receptor by
spontaneous mutations affecting the N-terminal extracellular domain. FEBS Lett. Jun
16;409(3):469-74, 1997
16. Gruters A, Schoneberg T, Biebermann H et al. Severe congenital hyperthyroidism
caused by a germ-line neo mutation in the extracellular portion of the thyrotropin receptor.
J Clin Endocrinol Metab. May;83(5):1431-6, 1998
17. Parma J, Duprez L, Van Sande J et al. Diversity and prevalence of somatic mutations in
the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin
Endocrinol Metab. Aug;82(8):2695-701, 1997
18. Kopp P, Muirhead S, Jourdain N et al. Congenital hyperthyroidism caused by a solitary
toxic adenoma harboring a novel somatic mutation (serine281-->isoleucine) in the
extracellular domain of the thyrotropin receptor. J Clin Invest. Sep 15;100(6):1634-9, 1997
19. Ho SC, Van Sande J, Lefort A et al. Effects of Mutations Involving the Highly Conserved
S281HCC Motif in the Extracellular Domain of the Thyrotropin (TSH) Receptor on TSH
Binding and Constitutive Activity. Endocrinology 142:2760-2767, 2001
20. Nakabayashi K, Kudo M, Kobilka B et al. Activation of the Luteinizing Hormone
Receptor Following Substitution of Ser-277 with Selective Hydrophobic Residues in the
Ectodomain Hinge Region. J Biol Chem. 275:30264-30271, 2000
21. Tanaka K, Chazenbalk GD, McLachlan SM et al. Thyrotropin receptor cleavage at site 1
does not involve a specific amino acid motif but instead depends on the presence of the
unique, 50 amino acid insertion. J Biol Chem. Jan 23;273(4):1959-63, 1998
22. Kosugi S, Matsuda A, Hai N et al. Aspartate-474 in the first exoplasmic loop of the
thyrotropin receptor is crucial for receptor activation. FEBS Lett. 1997 Apr 7;406(1-2):13941, 1997
23. Agretti P, De Marco G, Collecchi P et al. Proper targeting and activity of a
nonfunctioning thyroid-stimulating hormone receptor (TSHr) combining an inactivating
and activating TSHr mutation in one receptor. Eur J Biochem. Sep;270(18):3839-47, 2003
24. Tonacchera M, Chiovato L, Pinchera A et al. Hyperfunctioning thyroid nodules in toxic
multinodular goiter share activating thyrotropin receptor mutations with solitary toxic
adenoma. J Clin Endocrinol Metab. Feb;83(2):492-8. 1998
25. Kosugi S, Mori T, Shenker A. An anionic residue at position 564 is important for
maintaining the inactive conformation of the human lutropin/choriogonadotropin receptor.
1998 Mol Pharmacol. May;53(5):894-901.
26. Angelova K, Fanelli F, Puett D. A model for constitutive lutropin receptor activation
based on molecular simulation and engineered mutations in transmembrane helices 6
and 7. 2002 J Biol Chem. Aug 30;277(35):32202-13. Epub 2002 Jun 17.
27. Sohn J, Ryu K, Sievert G et al. Follicle-stimulating hormone interacts with exoloop 3 of
the receptor. J Biol Chem. Dec 20;277(51):50165-75, 2002
28. Ruy KS, Gilchrist RL, Tung CS et al. High affinity hormone binding to the extracellular
N-terminal Exodomain of the Follicle-stimulating hormone receptor is critically modulated
by exoloop 3. J Biol Chem. Oct 30;273(44):28953-58, 1998
29. Gilchrist RL, Ryu KS, Ji I et al. The luteinizing hormone/chorionic gonadotropin receptor
has distinct transmembrane conductors for cAMP and inositol phosphate signals. J Biol
Chem. Aug 9;271(32):19283-7, 1996
30. Ryu K, Lee H, Kim S et al. Modulation of high affinity hormone binding. Human
choriogonadotropin binding to the exodomain of the receptor is influenced by exoloop 2 of
the receptor. J Biol Chem. Mar 13;273(11):6285-91, 1998
31. Palczewski K, Kumasaka T, Hori T et al. Crystal structure of rhodopsin: A G proteincoupled receptor. Science. Aug 4;289(5480):739-45, 2000
32. Neumann S, Krause G, Chey S et al. A free carboxylate oxygen in the side chain of
position 674 in transmembrane domain 7 is necessary for TSH receptor activation. Mol
Endocrinol. Aug;15(8):1294-305, 2001
33. Kosugi S, Mori T, Shenker A. The role of Asp578 in maintaining the inactive
conformation of the human lutropin/choriogonadotropin receptor. J Biol Chem. Dec
13;271(50):31813-7, 1996
34. Lin Z, Shenker A, Pearlstein R. A model of the lutropin/choriogonadotropin receptor:
insights into the structural and functional effects of constitutively activating mutations.
Protein Eng. May;10(5):501-10, 1997
35. Fanelli F, Verhoef-Post M, Timmerman M et al. Insight into mutation-induced activation
of the luteinizing hormone receptor: molecular simulations predict the functional behavior
of engineered mutants at M398. Mol Endocrinol. Jun;18(6):1499-508. Epub 2004 Mar 11,
2004
36. Duprez L, Hermans J, Van Sande J et al. Two autonomous nodules of a patient with
multinodular goiter harbor different activating mutations of the thyrotropin receptor gene. J
Clin Endocrinol Metab. Jan;82(1):306-8, 1997
37. De Roux N, Polak M, Couet J et al. A neomutation of the thyroid-stimulating hormone
receptor in a severe neonatal hyperthyroidism. J Clin Endocrinol Metab. Jun;81(6):20236, 1996
38. Lavard L, Sehested A, Brock Jacobsen B et al. Long-term follow-Up of an infant with
thyrotoxicosis due to germline mutation of the TSH receptor gene (Met453Thr). Horm
Res.;51(1):43-6, 1999
39. Mircescu H, Parma J, Huot C et al. Hyperfunctioning malignant thyroid nodule in an 11-
year-old girl: pathologic and molecular studies. J Pediatr. Oct;137(4):585-7, 2000
40. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled
receptors. Endocr Rev. Feb;21(1):90-113, 2000
41. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at Gprotein-coupled receptors. Pharmacol Ther. Jul;99(1):25-44, 2003
42. Wess J. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol.Ther. 80
231-264, 1998
43. Neumann S, Krause G, Claus M et al. Structural determinants for G-protein activation
and selectivity in the second intracellular of the thyrotropin receptor. Endocrinology.
Jan;146(1):477-85, 2005
44. Kosugi S, Kohn LD, Akamizu T et al. The middle portion in the second cytoplasmic loop
of the thyrotropin receptor plays a crucial role in adenylate cyclase activation.
Mol.Endocrinol. 8 498-509, 1994
45. Fernandez LM, Puett D. Evidence for an important functional role of intracellular loop II
of the lutropin receptor. Mol Cell Endocrinol. Apr 4;128(1-2):161-9, 1997
46. Timossi C, Maldonado D, Vizcaino A et al. Structural determinants in the second
intracellular loop of the human follicle-stimulating hormone receptor are involved in G(s)
protein activation. Mol Cell Endocrinol. Mar 28;189(1-2):157-68, 2002
47. Fuhrer D, Lewis MD, Alkhafaji F et al. Biological activity of activating thyroid-stimulating
hormone receptor mutants depends on the cellular context. Endocrinology.
Sep;144(9):4018-30, 2003
48. Kosugi S, Okajima F, Ban T et al. Substitutions of different regions of the third
cytoplasmic loop of the thyrotropin (TSH) receptor have selective effects on constitutive,
TSH-, and TSH receptor autoantibody-stimulated phosphoinositide and 3',5'-cyclic
adenosine monophosphate signal generation. Mol.Endocrinol. 7 1009-1020, 1993
49. Wonerow P, Schoneberg T, Schultz G et al. Deletions in the third intracellular loop of
the thyrotropin receptor. A new mechanism for constitutive activation. J Biol Chem. Apr
3;273(14):7900-5, 1998
50. Janz JM, Farrens DL. Rhodopsin activation exposes a key hydrophobic binding site for
the transducin alpha-subunit C terminus. J Biol Chem. Jul 9;279(28):29767-73, 2004
51. Gabriel EM, Bergert ER, Grant CS et al. Germline Polymorphism of Codon 727 of
Human Thyroid-Stimulating Hormone Receptor Is Associated with Toxic Multinodular
Goiter J. Clin. Endocrinol. Metab., Sep; 84: 3328 – 3335,1999
52. Loos U, Hagner S, Bohr UR et al. Enhanced cAMP accumulation by the human
thyrotropin receptor variant with the Pro52Thr substitution in the extracellular domain. Eur
J Biochem. Aug 15;232(1):62-5, 1995
53. Tonacchera M and Pinchera A. Thyrotropin receptor polymorphisms and thyroid
diseases. J Clin Endocrinol Metab. Aug;85(8):2637-9, 2000
54. Ban Y, Greenberg DA, Concepcion ES et al. A Germline Single Nucleotide
Polymorphism at the Intracellular Domain of the Human Thyrotropin Receptor Does Not
Have a Major Effect on the Development of Graves' Disease. Thyroid Dec; 12 (12): 10791083, 2002
55. Chistiakov DA. Thyroid-stimulating hormone receptor and its role in Graves' disease. Mol
Genet Metab. Dec;80(4):377-88, 2003
56. Sykiotis GP, Neumann S, Georgopoulos NA et al. Functional significance of the
thyrotropin receptor germline polymorphism D727E. Biochem Biophys Res Commun. Feb
21;301(4):1051-6, 2003